Adjuvant properties of cytosine-phosphate-guanosine oligodeoxynucleotide in combination with various polycations in an ovalbumin-vaccine model

Nucleic Acid Therapeutics

Volumn 21, Issue 4, 2011, Pages 231-240

  Maubant, Sylvie ^a   Banissi, Claire ^a   Beck, Samantha ^a   Chauvat, Anne ^b   Carpentier, Antoine F ^a,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 28; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OVALBUMIN; POLYARGININE; POLYHISTIDINE; POLYLYSINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GLIOBLASTOMA; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CELLS, CULTURED; CHITOSAN; DRUG STABILITY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FREUND'S ADJUVANT; HISTIDINE; IMMUNE SERA; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PARTICLE SIZE; PEPTIDES; POLYAMINES; POLYLYSINE; VACCINATION;

EID: 80052235748     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0291     Document Type: Article

References (43)

1. BARCHET, W., WIMMENAUER, V., SCHLEE, M., and HART-MANN, G. (2008). Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol. 20, 389-395.
2. BAUER, M., REDECKE, V., ELLWART, J.W., SCHERER, B., KREMER, J.P., WAGNER, H., and LIPFORD, G.B. (2001a). Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J. Immunol. 166, 5000-5007. (Pubitemid 32280712)
3. B̈AUER, S., KIRSCHNING, C.J., HACKER, H., REDECKE, V., HAUSMANN, S., AKIRA, S., WAGNER, H., and LIPFORD, G.B. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 98, 9237-9242. (Pubitemid 32743900)
4. BORGES, O., SILVA, M., DE SOUSA, A., BORCHARD, G., JUNGINGER, H.E., and CORDEIRO-DA-SILVA, A. (2008). Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Im-munopharmacol. 8, 1773-1780.
5. BOURQUIN, C., ANZ, D., ZWIOREK, K., LANZ, A.L., FUCHS, S., WEIGEL, S., WURZENBERGER, C., VON DER BORCH, P., GOLIC, M., MODER, S., WINTER, G., COESTER, C., and ENDRES, S. (2008). Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 181, 2990-2998.
6. BUSCHLE, M., SCHMIDT, W., ZAUNER, W., MECHTLER, K., TRSKA, B., KIRLAPPOS, H., and BIRNSTIEL, M.L. (1997). Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. U.S.A. 94, 3256-3261. (Pubitemid 27157298)
7. CARPENTIER, A.F., AUF, G., and DELATTRE, J.Y. (2003). CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front. Biosci. 8, e115-e127.
8. CARPENTIER, A., METELLUS, P., URSU, R., ZOHAR, S., LA FITTE, F., BARRIE, M., MENG, Y., RICHARD, M., PARIZOT, C., LAIGLE-DONADEY, F., GOROCHOV, G., PSIMARAS, D., SANSON, M., TIBI, A., CHINOT, O., and CARPENTIER, A.F. (2010). Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neurol. Oncol. 12, 401-408.
9. CHO, H.J., TAKABAYASHI, K., CHENG, P.M., NGUYEN, M.D., CORR, M., TUCK, S., and RAZ, E. (2000). Im-munostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 8, 509-514. (Pubitemid 30313954)
10. CHU, R.S., TARGONI, O.S., KRIEG, A.M., LEHMANN, P.V., and HARDING, C.V. (1997). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631. (Pubitemid 27506276)
11. DAVIS, H.L., WEERATNA, R., WALDSCHMIDT, T.J., TY-GRETT, L., SCHORR, J., and KRIEG, A.M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876. (Pubitemid 28049329)
12. FRITZ, J.H., BRUNNER, S., BIRNSTIEL, M.L., BUSCHLE, M., GABAIN, A., MATTNER, F., and ZAUNER, W. (2004). The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22, 3274-3284. (Pubitemid 39078743)
13. FUTAKI, S. (2005). Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev. 57, 547-558. (Pubitemid 40255560)
14. FUTAKI, S., SUZUKI, T., OHASHI, W., YAGAMI, T., TANAKA, S., UEDA, K., and SUGIURA, Y. (2001). Arginine-rich pep-tides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836-5840.
15. GUY, B. (2007). The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517. (Pubitemid 46925379)
16. HAN, H.D., SONG, C.K., PARK, Y.S., NOH, K.H., KIM, J.H., HWANG, T., KIM, T.W., and SHIN, B.C. (2008). A chitosan hydrogel-based cancer drug delivery system exhibits syner-gistic antitumor effects by combining with a vaccinia viral vaccine. Int. J. Pharm. 350, 27-34. (Pubitemid 351146677)
17. HARTMANN, G., WEINER, G.J., and KRIEG, A.M. (1999). CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 96, 9305-9310. (Pubitemid 29374750)
18. HARTMANN, G., WEERATNA, R.D., BALLAS, Z.K., PAY-ETTE, P., BLACKWELL, S., SUPARTO, I., RASMUSSEN, W.L., WALDSCHMIDT, M., SAJUTHI, D., PURCELL, R.H., DAVIS, H.L., and KRIEG, A.M. (2000). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617-1624. (Pubitemid 30067282)
19. HEIT, A., SCHMITZ, F., O'KEEFFE, M., STAIB, C., BUSCH, D.H., WAGNER, H., and HUSTER, K.M. (2005). Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174, 4373-4380. (Pubitemid 40396020)
20. KADOWAKI, N., HO, S., ANTONENKO, S., MALEFYT, R.W., KASTELEIN, R.A., BAZAN, F., and LIU, Y.J. (2001). Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869. (Pubitemid 32983021)
21. KLINMAN, D.M., BARNHART, K.M., and CONOVER, J. (1999). CpG motifs as immune adjuvants. Vaccine 17, 19-25. (Pubitemid 28470728)
22. KLINMAN, D.M., YI, A.K., BEAUCAGE, S.L., CONOVER, J., and KRIEG, A.M. (1996). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleu-kin 12, and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93, 2879-2883. (Pubitemid 26116242)
23. KOVACS-NOLAN, J., LATIMER, L., LANDI, A., JENSSEN, H., HANCOCK, R.E., BABIUK, L.A., and VAN DRUNEN LITTEL-VAN DEN HURK, S. (2009). The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice. Vaccine 27, 2055-2064.
24. LINDBLAD, E.B. (2004). Aluminium adjuvants-in retrospect and prospect. Vaccine 22, 3658-3668.
25. LINGNAU, K., EGYED, A., SCHELLACK, C., MATTNER, F., BUSCHLE, M., and SCHMIDT, W. (2002). Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20, 3498-3508. (Pubitemid 35248074)
26. LüHRS, P., SCHMIDT, W., KUTIL, R., BUSCHLE, M., WAGNER, S.N., STINGL, G., and SCHNEEBERGER, A. (2002). Induction of specific immune responses by polycation-based vaccines. J. Immunol. 169, 5217-5226. (Pubitemid 35217193)
27. MAURER, T., HEIT, A., HOCHREIN, H., AMPENBERGER, F., O'KEEFFE,M., BAUER, S., LIPFORD, G.B., VABULAS, R.M., and WAGNER, H. (2002). CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32,2356-2364. (Pubitemid 34965899)
28. MENG, Y., CARPENTIER, A.F., CHEN, L., BOISSERIE, G., SIMON, J.M., MAZERON, J.J., and DELATTRE, J.Y. (2005). Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 116, 992-997. (Pubitemid 41209208)
29. MITCHELL, D.J., KIM, D.T., STEINMAN, L., FATHMAN, C.G., and ROTHBARD, J.B. (2000). Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56, 318-325.
30. NAKASE, I., NIWA, M., TAKEUCHI, T., SONOMURA, K., KAWABATA, N., KOIKE, Y., TAKEHASHI, M., TANAKA, S., UEDA, K., SIMPSON, J.C., JONES, A.T., SUGIURA, Y., and FUTAKI, S. (2004). Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011-1022. (Pubitemid 39625245)
31. REED, S.G., BERTHOLET, S., COLER, R.N., and FRIEDE, M. (2009). New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23-32.
32. SCHELLACK, C., PRINZ, K., EGYED, A., FRITZ, J.H., WITT-MANN, B., GINZLER, M., SWATOSCH, G., ZAUNER, W., KAST, C., AKIRA, S., VON GABAIN, A., BUSCHLE, M., and LINGNAU, K. (2006). IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24, 5461-5472. (Pubitemid 43831376)
33. SCHLOSSER, E., MUELLER, M., FISCHER, S., BASTA, S., BUSCH, D.H., GANDER, B., and GROETTRUP, M. (2008). TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26, 1626-1637.
34. SCHMIDT, W., BUSCHLE, M., ZAUNER, W., KIRLAPPOS, H., MECHTLER, K., TRSKA, B., and BIRNSTIEL, M.L. (1997). Cell-free tumour antigen peptide-based cancer vaccine. Proc. Natl. Acad. Sci. U.S.A. 94, 3262-3267. (Pubitemid 27157299)
35. SHIROTA, H., SANO, K., HIRASAWA, N., TERUI, T., OHU-CHI, K., HATTORI, T., SHIRATO, K., and TAMURA, G. (2001). Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 167, 66-74. (Pubitemid 32567762)
36. STANDLEY, S.M., MENDE, I., GOH, S.L., KWON, Y.J., B́EAUDETTE, T.T., ENGLEMAN, E.G., and FRECHET, J.M. (2007). Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug. Chem. 18, 77-83. (Pubitemid 46145996)
37. STILLS, H.F. (2005). Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46, 280-293.
38. TAKEMOTO, S., NISHIKAWA, M., OTSUKI, T., YAMAOKA, A., MAEDA, K., OTA, A., and TAKAKURA, Y. (2009). Enhanced generation of cytotoxic T lymphocytes by increased cytosolic deliveryofMHCclassIepitopefusedtomouseheatshockprotein 70 via polyhistidine conjugation. J. Control Release 135, 11-18.
39. TIGHE, H., TAKABAYASHI, K., SCHWARTZ, D., VAN NEST, G., TUCK, S., EIDEN, J.J., KAGEY-SOBOTKA, A., CRETICOS, P.S., LICHTENSTEIN, L.M., SPIEGELBERG, H.L., and RAZ, E. (2000). Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124-134. (Pubitemid 30482862)
40. WEERATNA, R., COMANITA, L., and DAVIS, H.L. (2003). CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol. Cell Biol. 81, 59-62. (Pubitemid 36237793)
41. YI, A.K., CHACE, J.H., COWDERY, J.S., and KRIEG, A.M. (1996). IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeox-ynucleotides. J. Immunol. 156, 558-564.
42. ZHANG, X.Q., DAHLE, C.E., WEINER, G.J., and SALEM, A.K. (2007). A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J. Pharm. Sci. 96, 3283-3292.
43. ZWIOREK, K., BOURQUIN, C., BATTIANY, J., WINTER, G., ENDRES, S., HARTMANN, G., and COESTER, C. (2008). Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 25, 551-562. (Pubitemid 351357729)